| ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia L Schönfeld, J Rinke, A Hinze, SN Nagel, V Schäfer, T Schenk, C Fabisch, ... Leukemia 36 (9), 2242-2249, 2022 | 22 | 2022 |
| Nilotinib vs nilotinib plus pegylated interferon α (Peg-IFN) induction and nilotinib or Peg-IFN maintenance therapy for newly diagnosed BCR-ABL1 positive chronic myeloid … A Hochhaus, A Burchert, S Saussele, GM Baerlocher, TH Brümmendorf, ... Blood 134, 495, 2019 | 18 | 2019 |
| PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells J Drube, T Ernst, M Pfirrmann, BV Albert, S Drube, D Reich, A Kresinsky, ... Oncotarget 9 (10), 9442, 2018 | 16 | 2018 |
| Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN) A Brioli, K Manz, M Pfirrmann, M Hänel, AC Schwarzer, G Prange-Krex, ... Journal of cancer research and clinical oncology 146, 749-759, 2020 | 13 | 2020 |
| Nilotinib vs nilotinib plus pegylated interferon-alpha2b induction and nilotinib or pegylated interferon-alpha2b maintenance therapy for newly diagnosed BCR-ABL+ chronic … A Hochhaus, S Saussele, GM Baerlocher, TH Brümmendorf, A Burchert, ... Blood 132, 460, 2018 | 10 | 2018 |
| Incidence of low level mutations in newly diagnosed CML patients: a substudy of the German Tiger Trial GN Franke, J Maier, K Wildenberger, C Günther, M Cross, T Ernst, ... Blood 130, 252, 2017 | 4 | 2017 |
| The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial J Hammersen, S Birndt, K Döhner, P Reuken, A Stallmach, P Sauerbrey, ... Leukemia 37 (9), 1879-1886, 2023 | 3 | 2023 |
| Therapie der chronischen myeloischen Leukämie A Hochhaus, C Fabisch, T Ernst Die Onkologie 25 (11), 971-984, 2019 | 3 | 2019 |
| Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients … A Hochhaus, A Burchert, S Saussele, GM Baerlocher, J Mayer, ... Blood 142, 446, 2023 | 2 | 2023 |
| S157: NILOTINIB VS. NILOTINIB+ PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS … A Hochhaus, A Burchert, S Saußele, GM Baerlocher, J Mayer, ... HemaSphere 7, e4695659, 2023 | 2 | 2023 |
| Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry A Brioli, E Lomaia, C Fabisch, T Sacha, H Klamová, E Morozova, A Golos, ... Blood 140 (Supplement 1), 818-820, 2022 | 2 | 2022 |
| S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL. T Ernst, P Le Coutre, M Crysandt, TH Brümmendorf, GN Franke, T Illmer, ... HemaSphere 7, e34543a6, 2023 | 1 | 2023 |
| ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase T Ernst, L Schönfeld, J Rinke, A Hinze, SN Nagel, V Schäfer, T Schenk, ... Blood 140 (Supplement 1), 807-808, 2022 | 1 | 2022 |
| Modulation des L-Typ-Calciumkanals Cav1. 2 in diabetischer Kardiomyopathie C Fabisch | 1 | 2010 |
| Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era–analysis of the European LeukemiaNet Blast Phase Registry A Brioli, E Lomaia, C Fabisch, T Sacha, H Klamova, E Morozova, A Golos, ... Leukemia, 1-9, 2024 | | 2024 |
| P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL S Birndt, J Hammersen, K Döhner, P Reuken, P Sauerbrey, F La Rosée, ... HemaSphere 7 (S3), e2130832, 2023 | | 2023 |
| Health-related quality of life (HRQoL) in CML-patients at diagnosis compared to general population M Lorch, M Pfirrmann, C Fabisch, L Oberle, D Kohn, K Kohlbrenner, ... | | 2021 |
| Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+ Chronic Myeloid Leukemia (CML … T Ernst, S Saussele, A Burchert, GM Baerlocher, TH Bruemmendorf, ... ONCOLOGY RESEARCH AND TREATMENT 43, 104-104, 2020 | | 2020 |
| Therapy of chronic myelogenous leukemia A Hochhaus, C Fabisch, T Ernst Der Onkologe 25, 971-984, 2019 | | 2019 |
| Observational study on CML patients in any phase treated with ponatinib (Iclusig (R)) at any dose-The Ponderosa Project C Clauss, C Fabisch, T Ernst, T Schenk, S Saussele, H Tesch, J Mayer, ... ONCOLOGY RESEARCH AND TREATMENT 42, 219-219, 2019 | | 2019 |
